{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:36:10Z","timestamp":1794332170111,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xcrm.2024.101584","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:08:32Z","timestamp":1716304112000},"page":"101584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-197X","authenticated-orcid":false,"given":"Oliver","family":"Van Oekelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amatangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manishkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Pierceall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101584_bib1","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101584_bib2","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101584_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101584_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101584_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101584_bib7","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101584_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/15321819.2013.824898","article-title":"A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide","volume":"35","author":"Alzoman","year":"2014","journal-title":"J.\u00a0Immunoassay Immunochem."},{"key":"10.1016\/j.xcrm.2024.101584_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2024.101584_bib10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","article-title":"The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity","volume":"48","author":"John","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.xcrm.2024.101584_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.xcrm.2024.101584_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101584_bib13","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP\u03b2 translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib14","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1128\/MCB.00224-10","article-title":"Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression","volume":"30","author":"Ma","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101584_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.xcrm.2024.101584_bib16","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T\u00a0cells by inducing degradation of T\u00a0cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101584_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101584_bib19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T\u00a0cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib20","doi-asserted-by":"crossref","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8+ CD28\u2212 T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101584_bib21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T\u00a0cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.xcrm.2024.101584_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101584_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.xcrm.2024.101584_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101584_bib25","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib26","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1182\/blood-2018-99-111823","article-title":"Cyclophosphamide exerts significant immunomodulatory function in myeloma patients treated with pomalidomide and dexamethasone","volume":"132","author":"Croft","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib27","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed\/Refractory Multiple Myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101584_bib28","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and\u00a0dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2024.101584_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101584_bib30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101584_bib31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in\u00a0Vitro","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood.V128.22.1591.1591","article-title":"CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines","volume":"128","author":"Bjorklund","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib33","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1182\/blood-2019-126146","article-title":"Multidimensional Single Cell Analysis Shows Increased T\/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed\/Refractory Multiple Myeloma Patients","volume":"134","author":"Amatangelo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"van de Donk","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib35","series-title":"American Society of Gene and Cell Therapy Annual Meeting 2020","article-title":"Iberdomide Increases the Potency of the Anti-BCMA CAR T Cell Product Orvacabtagene Autoleucel (Orva-Cel)","author":"Soni","year":"2020"},{"key":"10.1016\/j.xcrm.2024.101584_bib36","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2024.101584_bib37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.2022015909","article-title":"Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma","volume":"140","author":"Gooding","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib39","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101584_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101571","article-title":"Pharmacodynamic changes in tumor and immune cells drive Iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory Multiple Myeloma","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.xcrm.2024.101584_bib41","series-title":"CATALYST: Cytometry dATa anALYSis Tools","author":"Crowell","year":"2020"},{"key":"10.1016\/j.xcrm.2024.101584_bib42","series-title":"Diffcyt: Differential Discovery in High-Dimensional Cytometry via High-Resolution Clustering","author":"Weber","year":"2019"},{"key":"10.1016\/j.xcrm.2024.101584_bib43","first-page":"e328","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet\u00a0Oncol."},{"key":"10.1016\/j.xcrm.2024.101584_bib44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nprot.2015.020","article-title":"Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm","volume":"10","author":"Zunder","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2024.101584_bib45","article-title":"Web-based analysis and publication of flow cytometry experiments","volume":"Chapter 10","author":"Kotecha","year":"2010","journal-title":"Current protocols in cytometry"},{"key":"10.1016\/j.xcrm.2024.101584_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.celrep.2019.06.049","article-title":"Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy","volume":"28","author":"Hartmann","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101584_bib47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF\u00a0workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.xcrm.2024.101584_bib48","series-title":"flowCore: flowCore: Basic Structures for Flow Cytometry Data","author":"Ellis","year":"2019"},{"key":"10.1016\/j.xcrm.2024.101584_bib49","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T15:15:27Z","timestamp":1718723727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124002763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666379124002763"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101584","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101571","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101584"}}